Italia markets closed

MDxHealth SA (0O8G.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
0,6920-0,0030 (-0,43%)
Alla chiusura: 10:46AM BST
Schermo intero
Chiusura precedente0,6950
Aperto0,6920
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno0,6920 - 0,6920
Intervallo di 52 settimane0,6920 - 0,6920
Volume370
Media VolumeN/D
Capitalizzazione382.613
Beta (5 anni mensile)0,91
Rapporto PE (ttm)N/D
EPS (ttm)-0,2150
Prossima data utiliN/D
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    MDxHealth Reports Half Year 2022 Results

    NEWS RELEASE - REGULATED INFORMATION25 AUGUST 2022, 4:00PM EDT, 22:00 CET MDxHealth Reports Half Year 2022 Results IRVINE, CA, and HERSTAL, BELGIUM – August 25, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today announced its financial results for the half year ended June 30, 2022. Michael K. McGarrity, CEO of mdxhealth, commented: “We are excited to report strong operating results for the first half of 2022, couple

  • GlobeNewswire

    Mdxhealth's New Share Capital Amount and New Number of Shares

    NEWS RELEASE - REGULATED INFORMATIONAugust 19, 2022, 4:00 PM EDT / 22:00 CET Mdxhealth's New Share Capital Amount and New Number of Shares IRVINE, CA, and HERSTAL, BELGIUM – August 19, 2022 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today a announces, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulate

  • GlobeNewswire

    Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results

    NEWS RELEASE – INSIDE AND REGULATED INFORMATIONAugust 2, 2022, 4:00PM EDT / 22:00 CET Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results Solidifies leadership in the precision diagnostics urology marketProvides the most comprehensive menu of advanced molecular tests for urology in prostate cancerEnhances scale with best-in-class commercial channel into urology communityExact Sciences to take portion of initial payment i